Loading…
← CockpitCompetitor Analysis › SI Shoulder Innovations, Inc.Open in the cockpit ↗

Shoulder Innovations, Inc.SICompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 82
Mkt cap
$432M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$2.71M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-74.2 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$20.65
1D+0.4%
1W-5.8%
1M+10.3%
3M-6.6%
6M+38.8%
YTD+44.4%
1Y+42.7%
ATR %5.3%
Beta0.47
52w lowhigh16.0% off high

What Shoulder Innovations does

Employees: 75

Shoulder Innovations at a glance

Size Shoulder Innovations (SI) is a United States Health Care company (Medical Specialties) with a market value of $432M, the 2783rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.65 on 18 Nov 2026.

Performance Over six months the shares gained 38.8%, against -21.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 54.9% over the last twelve months (peer median +1.4%); the operating margin is -54.4% (peer median 6.1%).

Valuation It trades at 5.5× enterprise value to sales against a peer median of 3.9× (6th most expensive of 19).

Capital Return on invested capital runs 74.2 points below its cost of capital (6.5% WACC).

Short interest Short interest is 3.4% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026SI 137Peer median 81
Six months, rebased to 100: Shoulder Innovations against the median of its 20 peers (local-currency closes).

Shoulder Innovations financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$64.5M$47.3M$31.6M$19.3M
Revenue growth—+50%+64%—
Gross profit$45.8M$33.0M$22.1M$13.6M
EBITDA-$30.7M-$23.1M-$12.5M-$9.22M
Net income-$33.4M-$40.4M-$15.6M-$12.7M
Free cash flow-$43.2M-$36.0M-$18.2M-$15.9M
Capital expenditure$7.76M$7.41M$4.01M$2.75M
Total debt$14.9M$15.0M$14.7M$14.5M

Quarterly statements and history in the cockpit →

Shoulder Innovations competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%MOBIREG1V6880261763300515300110CU63010979877603987002016468530300289688358688133MDXGMASS603309SI6-month return →1-month return →
Up and to the right = strong over both horizons. Shoulder Innovations is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×200×400×MOBIREG1V9877002016468530SIRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shoulder Innovations is the large dot.

Shoulder Innovations competitors and peer comparison

How Shoulder Innovations compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shoulder Innovations against its 20 peers (data as of 18 Nov 2026)
MeasureSIPeer medianRank in peer set
1-month return+10.3%-9.6%3rd highest of 21
6-month return+38.8%-21.1%2nd highest of 21
Distance from 52-week high-16.0%-44.8%2nd highest of 21
Revenue growth (TTM)+54.9%+1.4%3rd highest of 20
Operating margin-54.4%6.1%4th lowest of 20
EV / Sales5.5×3.9×6th most expensive of 19
ROIC minus cost of capital-74.2 pp-2.2 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shoulder Innovations SIUnited States$432M+39%+55%-54%5.5×n/an/a
Mobia Medical MOBIUnited States$434M+2%+105%-145%8.8×n/an/a
Revenio REG1V.HEFinland$428M-34%+44%10%4.0×18.5%+12.4%
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%11%4.8×20.6%+2.2%
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%13%n/an/an/a
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%27%3.5×-0.1%+15.6%
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%6%3.3×5.8%+0.3%
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%4.4×n/an/a
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%17.8×n/an/a
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%1.5×-1.0%-2.8%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%3.8×21.5%-11.7%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%410.3×n/an/a
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%8.2×36.0%-6.9%
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
MiMedx MDXGUnited States$464M-16%-23%-8%1.1×10.9%+11.0%
Eiken Chemical 4549.TJapan$466M-20%+4%6%1.6×n/an/a
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
908 Devices MASSUnited States$396M+36%+14%-33%4.6×41.7%+15.9%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%2.0×-5.9%+7.7%

Questions

Which companies are Shoulder Innovations's closest peers?
The cockpit's peer set: Mobia Medical (MOBI), Revenio (REG1V.HE), Guangzhou Jet Bio-Filtration (688026.SS), China Isotope & Radiation (1763.HK), Hunan Sundy Science and Technology (300515.SZ), Huaren Pharmaceutical (300110.SZ), Clarity Pharmaceuticals (CU6.AX), Ningbo Tianyi Medical Appliance (301097.SZ).
Is Shoulder Innovations expensive compared with its peers?
On ev / sales it trades at 5.5× against a peer median of 3.9×, 6th most expensive of 19 in its peer set.
How has Shoulder Innovations stock performed?
Over six months to 18 Nov 2026 the shares returned +38.8% against -21.1% for the median peer; over one year +42.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.